退行性二尖瓣修复患者的室性心律失常:患病率及对生存的影响
基于全国保险数据库比较伴或不伴心律失常性二尖瓣脱垂患者退行性二尖瓣修复后的长期生存。共纳入20,980例,伴心律失常性二尖瓣脱垂占8.3%。外科修复后伴心律失常者5年生存优于不伴者,而TEER后伴心律失常者5年生存显著更差。
要点
- 心律失常性二尖瓣脱垂在外科修复后未显示更差生存,5年生存86%对81%。
- TEER后伴心律失常性二尖瓣脱垂者5年生存34%,显著低于不伴者的43%。
- 外科修复后伴心律失常者ICD植入率更高(1.3%对0.4%)。
核心结论
- 心律失常性二尖瓣脱垂与外科二尖瓣修复后更差生存无关,但与TEER后显著更差生存相关。
研究设计与样本
- 全国保险数据库回顾性队列研究,比较伴与不伴心律失常性二尖瓣脱垂患者退行性二尖瓣修复后的长期生存。
- 共纳入20,980例患者,中位随访3.8年(四分位距1.5-6.6年),采用多变量校正基线差异。
- 主要结局为5年生存,次要结局为ICD植入及室性心律失常相关再入院。
主要发现
- 20,980例中1745例(8.3%)存在心律失常性二尖瓣脱垂,其中1121例(64%)接受外科修复,624例(36%)接受TEER。
- 外科修复后5年生存:伴心律失常性二尖瓣脱垂者86%,不伴者81%(HR 0.79;95%CI 0.64-0.97;P=.02)。
- TEER后5年生存:伴心律失常性二尖瓣脱垂者34%,不伴者43%(HR 1.26;95%CI 1.07-1.49;P<.001)。
- 外科修复后伴心律失常者ICD植入率更高(1.3%对0.4%;P<.01),TEER后两组相近(0.6%对0.4%;P=.5)。
临床怎么用
- 对伴心律失常性二尖瓣脱垂的退行性二尖瓣反流患者,选择外科修复还是TEER时应考虑其生存差异。
- 外科修复后需关注心律失常者ICD植入率较高的情况。
局限性
- 原文未报告基于保险数据库的回顾性设计、心律失常定义及残余混杂等具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventricular arrhythmias occur in a subset of patients with mitral valve prolapse; however, their impact on postoperative survival after degenerative mitral repair is unclear. METHODS: We compared long-term survival after degenerative mitral repair in patients presenting with and without arrhythmic mitral valve prolapse (defined by degenerative mitral regurgitation and ventricular arrhythmias) in a national insurance database. Our primary outcome was survival up to 5 years; secondary outcomes were implantable cardiac defibrillator (ICD) and ventricular arrhythmia-related readmissions. Multivariable adjustment accounted for baseline differences. Median follow-up was 3.8 years (interquartile range, 1.5-6.6 years). RESULTS: Among 20,980 patients, 1745 (8.3%) had arrhythmic mitral valve prolapse, of whom 1121 (64%) underwent surgical repair and 624 (36%) underwent transcatheter edge-to-edge repair (TEER). The 5-year survival after surgical repair was 86% in patients with arrhythmic mitral valve prolapse compared to 81% in patients without (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.64-0.97; P = .02). The 5-year survival after TEER was 34% in patients with arrhythmic mitral valve prolapse compared to 43% in patients without (HR, 1.26; 95% CI, 1.07-1.49; P < .001). Rates of ICD were higher following surgery in patients with arrhythmia (1.3% vs 0.4%; P < .01) and similar following TEER in the 2 groups (0.6% vs 0.4%; P = .5). CONCLUSIONS: Arrhythmic mitral valve prolapse is not associated with worse survival after surgical mitral repair; however, arrhythmic mitral valve prolapse is associated with significantly worse survival after TEER. Prospective mechanistic studies are needed to elucidate the pathophysiology of and inform treatment choices in patients with arrhythmic mitral valve prolapse.
引用
- Sharew B, Chikwe J, Sallam A, et al. Ventricular arrhythmias in patients undergoing degenerative mitral repair: Prevalence and impact on survival. J Thorac Cardiovasc Surg. 2025. PMID: 40849061. doi:10.1016/j.jtcvs.2025.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。